Hypertriglyceridemia.
Brahm A, Hegele RA.
Nutrients. 2013 Mar 22;5(3):981-1001. doi: 10.3390/nu5030981.
The spectrum of type III hyperlipoproteinemia.
Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P.
J Clin Lipidol. 2018 Nov-Dec;12(6):1383-1389. doi: 10.1016/j.jacl.2018.09.006. Epub 2018 Sep 14.
Emerging agents targeting triglycerides.
Prakash Y, Bhatt DL, Malick WA.
Curr Opin Lipidol. 2025 Jun 1;36(3):119-129. doi: 10.1097/MOL.0000000000000979. Epub 2025 Feb 18.
The clinical and laboratory investigation of dysbetalipoproteinemia.
Boot CS, Luvai A, Neely RDG.
Crit Rev Clin Lab Sci. 2020 Nov;57(7):458-469. doi: 10.1080/10408363.2020.1745142. Epub 2020 Apr 7.
Umbrella Review on Non-Statin Lipid-Lowering Therapy.
Beshir SA, Hussain N, Elnor AA, Said ASA.
J Cardiovasc Pharmacol Ther. 2021 Sep;26(5):437-452. doi: 10.1177/10742484211002943. Epub 2021 Apr 9.
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists.
Cooreman MP, Vonghia L, Francque SM.
Diabetes Res Clin Pract. 2024 Jun;212:111688. doi: 10.1016/j.diabres.2024.111688. Epub 2024 May 1.
Phytosterols, Phytostanols, and Lipoprotein Metabolism.
Gylling H, Simonen P.
Nutrients. 2015 Sep 17;7(9):7965-77. doi: 10.3390/nu7095374.
Risk of Chronic Disease after an Episode of Marasmus, Kwashiorkor or Mixed-Type Severe Acute Malnutrition in the Democratic Republic of Congo: The Lwiro Follow-Up Study.
Mwene-Batu P, Bisimwa G, Donnen P, Bisimwa J, Tshongo C, Dramaix M, Hermans MP, Briend A.
Nutrients. 2022 Jun 14;14(12):2465. doi: 10.3390/nu14122465.
The Treatment of Disorders of Lipid Metabolism.
Parhofer KG.
Dtsch Arztebl Int. 2016 Apr 15;113(15):261-8. doi: 10.3238/arztebl.2016.0261.
[Fibrates - the present state of art].
Krysiak R, Rudzki H, Handzlik-Orlik G, Gdula-Dymek A, Okopień B.
Pol Merkur Lekarski. 2016 Jun;40(240):341-4.
